A Phase I, First-In-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
Latest Information Update: 10 Nov 2023
Price :
$35 *
At a glance
- Drugs PRJ1 3024 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 05 Apr 2022 Planned End Date changed from 1 Aug 2024 to 15 Aug 2024.
- 05 Apr 2022 Planned primary completion date changed from 1 Feb 2024 to 15 Feb 2024.
- 05 Apr 2022 Status changed from not yet recruiting to recruiting.